Medicenna Therapeutics Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
20
- Stock Symbol
-
MDNA
- Investments
-
1
- Share Price
-
$0.67
- (As of Tuesday Closing)
Medicenna Therapeutics General Information
Description
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
Contact Information
Website
www.medicenna.comCorporate Office
- 2 Bloor Street West
- 7th Floor
- Toronto, Ontario M4W 3E2
- Canada
Corporate Office
- 2 Bloor Street West
- 7th Floor
- Toronto, Ontario M4W 3E2
- Canada
Medicenna Therapeutics Stock Performance
As of 17-Jun-2025, Medicenna Therapeutics’s stock price is $0.67. Its current market cap is $52.4M with 78.2M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.67 | $0.66 | $0.60 - $1.94 | $52.4M | 78.2M | 31.7K | -$0.27 |
Medicenna Therapeutics Financials Summary
As of 31-Dec-2024, Medicenna Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Mar-2024 | FY 2023 31-Mar-2023 | FY 2022 31-Mar-2022 |
|---|---|---|---|---|
| EV | 67,467 | 79,261 | 18,668 | 55,108 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (20,546) | (19,757) | (8,276) | (18,025) |
| Net Income | (19,613) | (18,873) | (7,589) | (18,001) |
| Total Assets | 22,463 | 14,161 | 26,945 | 18,788 |
| Total Debt | 121 | 0 | 0 | 0 |
Medicenna Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Medicenna Therapeutics Comparisons
Industry
Financing
Details
Medicenna Therapeutics Competitors (55)
One of Medicenna Therapeutics’s 55 competitors is Xilio Therapeutics, a Formerly VC-backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Xilio Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Immunocore | Formerly VC-backed | Abingdon, United Kingdom | ||||
| TScan Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Black Diamond Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Cullinan Therapeutics | Formerly VC-backed | Cambridge, MA |
Medicenna Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Medicenna Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Medicenna Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Medicenna Therapeutics Acquisitions (1)
Medicenna Therapeutics’s most recent deal was a Merger/Acquisition with A2 Acquisition. The deal was made on 01-Mar-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| A2 Acquisition | 01-Mar-2017 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Medicenna Therapeutics FAQs
-
When was Medicenna Therapeutics founded?
Medicenna Therapeutics was founded in 2011.
-
Where is Medicenna Therapeutics headquartered?
Medicenna Therapeutics is headquartered in Toronto, Canada.
-
What is the size of Medicenna Therapeutics?
Medicenna Therapeutics has 20 total employees.
-
What industry is Medicenna Therapeutics in?
Medicenna Therapeutics’s primary industry is Biotechnology.
-
Is Medicenna Therapeutics a private or public company?
Medicenna Therapeutics is a Public company.
-
What is Medicenna Therapeutics’s stock symbol?
The ticker symbol for Medicenna Therapeutics is MDNA.
-
What is the current stock price of Medicenna Therapeutics?
As of 17-Jun-2025 the stock price of Medicenna Therapeutics is $0.67.
-
What is the current market cap of Medicenna Therapeutics?
The current market capitalization of Medicenna Therapeutics is $52.4M.
-
Who are Medicenna Therapeutics’s competitors?
Xilio Therapeutics, Immunocore, TScan Therapeutics, Black Diamond Therapeutics, and Cullinan Therapeutics are some of the 55 competitors of Medicenna Therapeutics.
-
What is Medicenna Therapeutics’s annual earnings per share (EPS)?
Medicenna Therapeutics’s EPS for 12 months was -$0.27.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
